| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2018-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7883e95ea966ff81bf062ee7e67279f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97027daeb2a807da9b96f8211460e8ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a3006bca4fd3f7f86620d9642eba9fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d279153ea617123f26ba641a95f8ac4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1779aa5f46e06772884a3d6ba6021203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_723fcb2bd4f785c0935057046d6ad044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c95625c5d1be087b18beb0974abfb6c4 |
| publicationDate |
2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020123256-A1 |
| titleOfInvention |
Cytotoxicity-inducing therapeutic agent |
| abstract |
The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, uses of such multispecific antigen-binding molecules, etc. The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity and high stability, which comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing RNF43, it is possible to produce novel pharmaceutical compositions comprising the multispecific antigen-binding molecules for treating or preventing various cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660340-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649293-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11505605-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11485790-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649262-B2 |
| priorityDate |
2017-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |